E. Kettner

4.9k total citations · 1 hit paper
38 papers, 3.0k citations indexed

About

E. Kettner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, E. Kettner has authored 38 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in E. Kettner's work include Colorectal Cancer Treatments and Studies (19 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Gastric Cancer Management and Outcomes (11 papers). E. Kettner is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Gastric Cancer Management and Outcomes (11 papers). E. Kettner collaborates with scholars based in Germany, United States and Estonia. E. Kettner's co-authors include Karsten Ridwelski, J. Fahlke, H Schramm, Bernd Doerken, Ingo Schmidt‐Wolf, Karin Weigang-Koehler, Klaus Gellert, Marco Niedergethmann, P. Neuhaus and Wolf O. Bechstein and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

E. Kettner

36 papers receiving 3.0k citations

Hit Papers

Adjuvant Chemotherapy With Gemcitabine vs Observation in ... 2007 2026 2013 2019 2007 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
    2007 1.8k citations Helmut Oettle, Stefan Post et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Kettner Germany 16 2.6k 1.0k 887 710 647 38 3.0k
Pascal Artru France 28 3.1k 1.2× 1.4k 1.4× 854 1.0× 569 0.8× 979 1.5× 132 3.7k
Maeve A. Lowery United States 30 2.6k 1.0× 878 0.9× 1.4k 1.5× 390 0.5× 1.2k 1.9× 141 3.5k
Heung-Moon Chang South Korea 25 1.4k 0.5× 908 0.9× 673 0.8× 261 0.4× 284 0.4× 79 2.1k
Geneviève Monges France 30 3.0k 1.1× 1.2k 1.1× 1.5k 1.7× 644 0.9× 666 1.0× 77 4.3k
Z. Alexander Cao United States 18 3.7k 1.4× 1.1k 1.1× 763 0.9× 165 0.2× 769 1.2× 40 4.4k
Nicola Personeni Italy 28 2.0k 0.8× 943 0.9× 803 0.9× 283 0.4× 568 0.9× 89 3.1k
Linus Ho United States 28 2.0k 0.8× 1.5k 1.5× 1.5k 1.7× 604 0.9× 559 0.9× 57 3.1k
Gina M. Vaccaro United States 20 1.2k 0.5× 833 0.8× 1.1k 1.3× 167 0.2× 373 0.6× 52 2.3k
John Kauh United States 28 1.4k 0.5× 660 0.6× 640 0.7× 480 0.7× 353 0.5× 106 3.0k
Vera Gorbounova Russia 13 2.2k 0.8× 1.8k 1.8× 280 0.3× 407 0.6× 354 0.5× 23 3.2k

Countries citing papers authored by E. Kettner

Since Specialization
Citations

This map shows the geographic impact of E. Kettner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Kettner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Kettner more than expected).

Fields of papers citing papers by E. Kettner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Kettner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Kettner. The network helps show where E. Kettner may publish in the future.

Co-authorship network of co-authors of E. Kettner

This figure shows the co-authorship network connecting the top 25 collaborators of E. Kettner. A scholar is included among the top collaborators of E. Kettner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Kettner. E. Kettner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haas, Michael, Steffen Ormanns, Stephan Krüger, et al.. (2017). Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. British Journal of Cancer. 116(11). 1462–1469. 23 indexed citations
2.
Mohnike, Konrad, Max Seidensticker, Peter Hass, et al.. (2016). Haemorrhagic Complications and Symptomatic Venous Thromboembolism in Interventional Tumour Ablations: The Impact of Peri-interventional Thrombosis Prophylaxis. CardioVascular and Interventional Radiology. 39(12). 1716–1721. 10 indexed citations
3.
Seidensticker, Ricarda, Timm Denecke, Patrick Kraus, et al.. (2011). Matched-Pair Comparison of Radioembolization Plus Best Supportive Care Versus Best Supportive Care Alone for Chemotherapy Refractory Liver-Dominant Colorectal Metastases. CardioVascular and Interventional Radiology. 35(5). 1066–1073. 115 indexed citations
4.
Stemmler, Hans‐Joachim, Werner Freier, G. Gitsch, et al.. (2011). Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer. 104(7). 1071–1078. 29 indexed citations
5.
6.
Moehler, Markus, E. Kettner, S. Hegewisch-Becker, et al.. (2009). Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer. Journal of Clinical Oncology. 27(15_suppl). e15502–e15502. 3 indexed citations
7.
8.
Dresemann, G., Mark Rosenthal, Klaus Hoeffken, et al.. (2007). Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) - An international open label randomised phase III study (ambrosia-study). Neuro-Oncology. 9(4). 2 indexed citations
9.
10.
Oettle, Helmut, Stefan Post, P. Neuhaus, et al.. (2007). Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. JAMA. 297(3). 267–267. 1754 indexed citations breakdown →
11.
Fahlke, J., Karsten Ridwelski, E. Kettner, et al.. (2007). A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer. Chemotherapy. 53(6). 454–460. 6 indexed citations
12.
Boeck, Stefan, K. Weigang-Köhler, Martin Fuchs, et al.. (2007). Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Annals of Oncology. 18(4). 745–751. 59 indexed citations
13.
Ridwelski, Karsten, J. Fahlke, Ralf Kühn, et al.. (2006). Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma. European Journal of Surgical Oncology. 32(3). 297–302. 10 indexed citations
14.
15.
Höchster, Howard S., E. Kettner, H. Kröning, et al.. (2005). Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer. 5(4). 257–262. 12 indexed citations
16.
Minckwitz, Gϋnter von, W. Jonat, Peter A. Fasching, et al.. (2005). A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Research and Treatment. 89(2). 165–172. 128 indexed citations
17.
Kornmann, Marko, Wolfgang Schwabe, Silvia Sander, et al.. (2003). Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.. PubMed. 9(11). 4116–24. 136 indexed citations
18.
Ridwelski, Karsten, J. Fahlke, H. Kröning, et al.. (2001). Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Annals of Oncology. 12(1). 47–51. 136 indexed citations
19.
Kröning, H., Michael Täger, Annelore Ittenson, et al.. (1997). Overproduction of IL-7, IL-10 and TGF-β1 in Multiple Myeloma. Acta Haematologica. 98(2). 116–118. 19 indexed citations
20.
Köhler, Uwe, et al.. (1997). Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.. PubMed. 24(5 Suppl 17). S17–40. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pascal Artru Breakdown of academic impact, for papers by Maeve A. Lowery Breakdown of academic impact, for papers by Heung-Moon Chang Breakdown of academic impact, for papers by Geneviève Monges Breakdown of academic impact, for papers by Z. Alexander Cao Breakdown of academic impact, for papers by Nicola Personeni Breakdown of academic impact, for papers by Linus Ho Breakdown of academic impact, for papers by Gina M. Vaccaro Breakdown of academic impact, for papers by John Kauh Breakdown of academic impact, for papers by Vera Gorbounova
Rankless by CCL
2026